Eltrombopag: wielding a double-edged sword?
- PMID: 31196876
- DOI: 10.1182/blood.2019001327
Eltrombopag: wielding a double-edged sword?
Conflict of interest statement
Conflict-of-interest disclosure: The author declares no competing financial interests.
Comment on
-
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag.Blood. 2019 Jun 13;133(24):2575-2585. doi: 10.1182/blood.2019000478. Epub 2019 Apr 16. Blood. 2019. PMID: 30992268 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical

